-
Melt Drops [URGENT REPORT 2026] MeltDrops Shocking Boom Why Everyone Is Talking About This Weight Loss Supplement
New York City, NY, May 31, 2026 (GLOBE NEWSWIRE) — In an era where consumers are increasingly seeking convenience, sustainability, and innovation in the products they buy, a new category of compact, dissolvable products known as “Melt Drops” is drawing attention from retailers, industry experts, and consumers alike. Transform your wellness routine with Melt Drops…
-
Crypto News Today: AlphaPepe Hits $1.38M Raised While Bitcoin Price Prediction Targets $250K
MONACO, May 30, 2026 (GLOBE NEWSWIRE) — Crypto news today is turning toward AlphaPepe after the project announced that its presale has crossed $1.38 million in total capital raised. Stage 17 is live at $0.01804 per token, the holder count has passed 9,000, the AlphaSwap AI DEX demo has surpassed 5,000 active users, and AlphaPepe…
-
Nokia Corporation – Managers’ transactions (Hanrahan)
May 31, 2026 06:00 ET | Source: Nokia Oyj Nokia CorporationManagers’ transactions31 May 2026 at 13:00 EEST Nokia Corporation – Managers’ transactions (Hanrahan) Transaction notification under Article 19 of EU Market Abuse Regulation.____________________________________________Person subject to the notification requirementName: Hanrahan, VictoriaPosition: Other senior manager Issuer: Nokia CorporationLEI: 549300A0JPRWG1KI7U06Notification type: INITIAL NOTIFICATIONReference number: 158758/5/6____________________________________________Transaction date: 2026-05-26Venue: XNYSInstrument…
-
Precede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight™ to Decode MET-Driven Biology and Resistance in Advanced NSCLC
Data include assessment of MET expression, tumor and immune pathway activity, and lineage plasticity from just 1 mL of plasma in advanced NSCLC Plasma MET test showed high concordance with tissue IHC/FISH in EGFR-mutated NSCLC following progression on first-line targeted therapy (AUC=0.97) Baseline and longitudinal profiling in METex14 skipping NSCLC identified biology associated with therapeutic…
-
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer In head and neck cancer, IMA401 treatment at recommended Phase 2 dose (RP2D) with or without pembrolizumab resulted in a 29% confirmed ORR (4/14), 64% DCR (9/14) and mDOR…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
